These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 34477993

  • 1. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
    Karadag O, Dalkilic E, Ayan G, Kucuksahin O, Kasifoglu T, Yilmaz N, Koca SS, Yazisiz V, Erten PT, Sayarlioglu M, Terzioglu ME, Erten S, Kalyoncu U.
    Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
    [Abstract] [Full Text] [Related]

  • 2. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H, Tanaka Y, Sano S, Kameda H, Taniguchi A, Kashiwagi T, Kawaberi T, Kimura J, Morita A.
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [Abstract] [Full Text] [Related]

  • 3. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
    Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS.
    Arthritis Res Ther; 2023 Jun 23; 25(1):109. PubMed ID: 37353788
    [Abstract] [Full Text] [Related]

  • 4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb 23; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

  • 5. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs.
    Khraishi MM, Remple VP, Silverberg S, Stewart JC, Florica B, Bessette L.
    J Rheumatol; 2022 May 23; 49(5):454-464. PubMed ID: 35033999
    [Abstract] [Full Text] [Related]

  • 6. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis.
    Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N.
    Rheumatology (Oxford); 2017 Apr 01; 56(4):603-612. PubMed ID: 28013211
    [Abstract] [Full Text] [Related]

  • 7. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W.
    Arthritis Res Ther; 2024 Feb 15; 26(1):50. PubMed ID: 38360699
    [Abstract] [Full Text] [Related]

  • 8. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study.
    Conaghan PG, Alten R, Deodhar A, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Strand V.
    RMD Open; 2020 Jun 15; 6(2):. PubMed ID: 32611650
    [Abstract] [Full Text] [Related]

  • 9. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P, Psaltis D, Georgiadis A, Katsifis G, Theodoridou A, Gazi S, Sidiropoulos P, Tektonidou MG, Bounas A, Kandyli A, Vounotrypidis P, Sakellariou GT, Vassilopoulos D, Huang Z, Petrikkou E, Boumpas D.
    Rheumatol Int; 2023 Oct 15; 43(10):1871-1883. PubMed ID: 37402886
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, PSUMMIT 2 Study Group.
    Ann Rheum Dis; 2014 Jun 15; 73(6):990-9. PubMed ID: 24482301
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb 15; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, Quartuccio L, Egan CG, Lo Monaco A, Benucci M, Salaffi F, Semeraro A, Parisi S, Ceccarelli F, Piazza I, Foti R.
    Rheumatol Int; 2020 Feb 15; 40(2):263-272. PubMed ID: 31435754
    [Abstract] [Full Text] [Related]

  • 13. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
    Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B.
    RMD Open; 2019 Feb 15; 5(2):e000984. PubMed ID: 31413869
    [Abstract] [Full Text] [Related]

  • 14. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep 15; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 15. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.
    Rheumatology (Oxford); 2020 Jul 01; 59(7):1640-1650. PubMed ID: 31665497
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.